Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia
Michael Andreeff(The University of Texas MD Anderson Cancer Center), Kensuke Kojima(Kōchi University), David Bowen(University of Tennessee Health Science Center), Vivian Ruvolo(Hormel (United States)), Graciela M. Nogueras‐González(The University of Texas MD Anderson Cancer Center), Roger Strair(Johnson University), Swaminathan P. Iyer(The University of Texas MD Anderson Cancer Center), Jianguo Zhi(Roche (Switzerland)), Monica Reckner(Center for Innovation), Karen Yee(University Health Network), Xuelin Huang(The University of Texas MD Anderson Cancer Center), Steven Blotner, Giovanni Martinelli(University of Bologna), Lori Jukofsky(Center for Innovation), Gwen Nichols(Center for Innovation), Mark Kirschbaum(Cyclacel Pharmaceuticals (United States)), Sarit Assouline(Jewish General Hospital), Paresh Vyas(University of Oxford), Ruediger Rueger(Onkovis (Germany)), Gong Chen(Center for Innovation), Peter J. Bridge(Center for Innovation), Bradford Graves(Jnana Therapeutics (United States)), Steve Middleton(Center for Innovation), Leslie Popplewell(City Of Hope National Medical Center), Mark W. Drummond(Beatson West of Scotland Cancer Centre), Kevin R. Kelly(Keck Hospital of USC)
Cited by 355
Related Papers
Clinical and biological implications of driver mutations in myelodysplastic syndromes
|Blood|2013|1.8k
Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>
|New England Journal of Medicine|2013|1.7k